Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia.
Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA. Jaglowski SM, et al. Among authors: heerema na. Br J Haematol. 2012 Oct;159(1):82-7. doi: 10.1111/j.1365-2141.2012.09239.x. Epub 2012 Jul 25. Br J Haematol. 2012. PMID: 22831395 Free PMC article.
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. Lin TS, et al. Among authors: heerema na. J Clin Oncol. 2009 Dec 10;27(35):6012-8. doi: 10.1200/JCO.2009.22.6944. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826119 Free PMC article. Clinical Trial.
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101.
Jones JA, Ruppert AS, Zhao W, Lin TS, Rai K, Peterson B, Larson RA, Marcucci G, Heerema NA, Byrd JC. Jones JA, et al. Among authors: heerema na. Leuk Lymphoma. 2013 Dec;54(12):2654-9. doi: 10.3109/10428194.2013.788179. Epub 2013 May 9. Leuk Lymphoma. 2013. PMID: 23547837 Free PMC article.
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
Cohen JB, Ruppert AS, Heerema NA, Andritsos LA, Jones JA, Porcu P, Baiocchi R, Christian BA, Byrd JC, Flynn J, Penza S, Devine SM, Blum KA. Cohen JB, et al. Among authors: heerema na. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):278-285.e1. doi: 10.1016/j.clml.2014.12.012. Epub 2014 Dec 31. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25660723
Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA. Miller CR, et al. Among authors: heerema na. Br J Haematol. 2015 Jul;170(2):200-7. doi: 10.1111/bjh.13422. Epub 2015 Apr 19. Br J Haematol. 2015. PMID: 25891862 Free PMC article.
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Jaglowski SM, et al. Among authors: heerema na. Blood. 2015 Aug 13;126(7):842-50. doi: 10.1182/blood-2014-12-617522. Epub 2015 Jun 26. Blood. 2015. PMID: 26116658 Free PMC article. Clinical Trial.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Maddocks KJ, et al. Among authors: heerema na. JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218. JAMA Oncol. 2015. PMID: 26182309 Free PMC article.
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Stephens DM, et al. Among authors: heerema na. Am J Hematol. 2015 Nov;90(11):967-9. doi: 10.1002/ajh.24125. Epub 2015 Oct 12. Am J Hematol. 2015. PMID: 26202978 Free PMC article.
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA. Rogers KA, et al. Among authors: heerema na. Br J Haematol. 2018 Jan;180(2):259-266. doi: 10.1111/bjh.15035. Epub 2017 Nov 28. Br J Haematol. 2018. PMID: 29193006 Free article.
357 results